Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours
Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab…
Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab…